Previous Close | 7.53 |
Open | 7.62 |
Bid | 7.50 x 1000 |
Ask | 7.82 x 1200 |
Day's Range | 7.62 - 8.00 |
52 Week Range | 5.10 - 19.57 |
Volume | |
Avg. Volume | 33,370 |
Market Cap | 20.737M |
Beta (5Y Monthly) | -1.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -22.38 |
Earnings Date | Mar 19, 2024 - Mar 23, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for KALA
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually. A pre-recorded fireside chat will be made available beginning on Tuesday, February 13, 2024 at 12:00 p.m.
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,125 shares of its common stock to one new employee. The stock options were granted on January 16, 2024. The grant was